Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn Study

Moshe Mittelman, David H. Henry, John Glaspy, Anil Tombak, Rosemary Anne Harrup, Krzysztof Madry, Barbara Grabowska, Uwe Platzbecker, Tyson Lee, Katharina Modelska

Blood (2023) 142 (Supplement 1): 195.

https://doi.org/10.1182/blood-2023-180749

Published: 2023

Journal Articles

Use of Thrombopoietin Agonists in Immune Thrombocytopenia Purpura

Maya Charan, Colm Somers, David H. Henry

Blood (2022) 140 (Supplement 1): 11267–11268.

https://doi.org/10.1182/blood-2022-163356

Published: 2022

Journal Articles

Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels

David H. Henry, MD, John Glaspy, MD MPH, Rosemary Anne Harrup, Moshe Mittelman, MD, Amy Zhou, MD, Hetty E. Carraway, MD MBA, Charles Bradley, PhD, Gopal Saha, MD, Pamela Bartels, Robert Leong, Peony Yu, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142499

Published: 2020

Journal Articles

Efficacy and Safety of Ferric Carboxymaltose Injection in Reducing Anemia in Patients Receiving Chemotherapy for Non-Myeloid Malignancies: A Phase 3, Placebo-Controlled Study (IRON CLAD)

Jeffrey A. Gilreath, PharmD, Tamta Makharadze, MD, Ralph V. Boccia, MD, Anna Krupa, PharmD, David H. Henry, MD

Blood (2019) 134 (Supplement_1): 3535.

https://doi.org/10.1182/blood-2019-132135

Published: 2019

Journal Articles

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

Juan Carlos Ramos, MD BS, Richard F. Ambinder, MD, Joseph Sparano, MD, Jeannette Y Lee, PhD, Lawrence D Kaplan, MD, William Wachsman, MD PhD, David M. Aboulafia, MD, Ariela Noy, MD, Lee Ratner, MD PhD, David H. Henry, MD, Amy Chadburn, MD, Ethel Cesarman, MD PhD, Ronald T. Mitsuyasu, MD

Blood (2019) 134 (Supplement_1): 2872.

https://doi.org/10.1182/blood-2019-123558

Published: 2019

Journal Articles

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Blood (2019) 134 (Supplement_1): 130.

https://doi.org/10.1182/blood-2019-126787

Published: 2019

Journal Articles

A 19-Year Retrospective Analysis of Venous Thromboembolism Trends in Chemotherapy-Induced Anemia: Red Blood Cell Transfusion Versus Erythrocyte Stimulating Agent Administration

Emily Bryer, DO, Michael Kallan, MS, Ting-Shaun Chiu, MS, Katerina Scheuba, David H. Henry, MD

Blood (2019) 134 (Supplement_1): 4944.

https://doi.org/10.1182/blood-2019-129316

Published: 2019

Journal Articles

Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)

David H. Henry, MD, John Glaspy, MD MPH, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, Moshe Mittelman, MD, Amy Zhou, MD, Charles Bradley, PhD, Gopal Saha, MD, Pamela Bartels, Leong Robert, Kin-Hung P Yu, MD

Blood (2019) 134 (Supplement_1): 843.

https://doi.org/10.1182/blood-2019-128714

Published: 2019

Journal Articles

Ovarian Vein Thrombus: Is Treatment Necessary?

Trisha Sterlicchi, DO, David H. Henry, MD

Blood (2016) 128 (22): 1433.

https://doi.org/10.1182/blood.V128.22.1433.1433

Published: 2016

Journal Articles

A Longitudinal Definition of the Value of Cancer Drugs

Ohad Oren, MD, David H. Henry, MD

Blood (2016) 128 (22): 1185.

https://doi.org/10.1182/blood.V128.22.1185.1185

Published: 2016

Journal Articles

AMC-053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas

Erin Gourley Reid, MD, David Looney, MD, Frank Maldarelli, MD PhD, Ariela Noy, MD, David H. Henry, MD, David M. Aboulafia, MD, Juan Carlos Ramos, MD, Joseph Sparano, MD, Richard F. Ambinder, MD PhD, Jeannette Lee, PhD, Ronald T. Mitsuyasu, MD, William Wachsman, MD PhD

Blood (2016) 128 (22): 786.

https://doi.org/10.1182/blood.V128.22.786.786

Published: 2016

Journal Articles

AMC-085: A Pilot Trial of AVD and Brentuximab Vedotin in the Upfront Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma. A Trial of the AIDS Malignancy Consortium

Paul G. Rubinstein, MD, Page Moore, PhD, David H. Henry, MD, Lee Ratner, MD PhD, Elad Sharon, MD MPH, Ariela Noy, MD

Blood (2015) 126 (23): 1526.

https://doi.org/10.1182/blood.V126.23.1526.1526

Published: 2015

Journal Articles

Readmission Rates Due To Venous Thromboembolism In Cancer Patients After Abdominopelvic Surgery

Christine Klimowicz White, DO, Jessica Langholtz, Zackory T. Burns, Susan Kruse Sullivan, Kimberly Sallee, David H. Henry, MD

Blood (2013) 122 (21): 2940.

https://doi.org/10.1182/blood.V122.21.2940.2940

Published: 2013

Journal Articles

Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

Blood (2010) 115 (15): 3008–3016.

https://doi.org/10.1182/blood-2009-08-231613

Published: 2010

Journal Articles

A Retrospective Study On the Efficacy of Relative Dose Intensities of Non-Hodgkin's Lymphoma Treatments: Response to Chemotherapy and Overall Survival.

Gary J Wang, Keren Glinert, BA, David H. Henry, MD

Blood (2009) 114 (22): 1388.

https://doi.org/10.1182/blood.V114.22.1388.1388

Published: 2009

Journal Articles

Pre- and Post-National Coverage Determination (NCD) Hematologic Outcomes and Blood Utilization in Cancer Patients with Chemotherapy-Induced Anemia (CIA): Results From a Multicenter Chart Review.

David H. Henry, MD, Corey J. Langer, MD, FACP, R. Scott McKenzie, MD, Catherine Tak Piech, MBA, Mekré Senbetta, PharmD, Kathy L. Schulman, MA, Edward J. Stepanski, PhD

Blood (2009) 114 (22): 2491.

https://doi.org/10.1182/blood.V114.22.2491.2491

Published: 2009

Journal Articles

Venous Thromboembolism (VTE) and Survival in a Cancer Chemotherapy Outpatient Clinic: A Retrospective Chart Review Validation of a VTE Predictive Model.

Julia C. Kearney, Suzanne Rossi, BA, Keren Glinert, BA, David H. Henry, MD

Blood (2009) 114 (22): 2503.

https://doi.org/10.1182/blood.V114.22.2503.2503

Published: 2009

Journal Articles

Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim in Two Phase 3 Placebo-Controlled Clinical Trials.

Ilene Ceil Weitz, MD, Miguel A Sanz, David H. Henry, MD, Martin Schipperus, Bertrand Godeau, Michelle Gleeson, PhD, Mark Danese, Robert Deuson, PhD

Blood (2009) 114 (22): 891.

https://doi.org/10.1182/blood.V114.22.891.891

Published: 2009

Journal Articles

Manageable Side Effects of Intravenous Iron in a Community Practice

Nicole Brown, BA, David H. Henry, MD, Patricia A. Ford, MD

Blood (2008) 112 (11): 4687.

https://doi.org/10.1182/blood.V112.11.4687.4687

Published: 2008

Journal Articles

Assessment of the Anemia Work up Prior to the Use of Erythropoiesis Stimulating Agents (ESA) in Cancer Patients Undergoing Chemotherapy in a Community Oncology Practice

Carine Davila, Nicole Brown, BA, Suzanne Rossi, BA, David H. Henry, MD

Blood (2008) 112 (11): 4697.

https://doi.org/10.1182/blood.V112.11.4697.4697

Published: 2008

NARROW

Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn Study

Use of Thrombopoietin Agonists in Immune Thrombocytopenia Purpura

Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels

Efficacy and Safety of Ferric Carboxymaltose Injection in Reducing Anemia in Patients Receiving Chemotherapy for Non-Myeloid Malignancies: A Phase 3, Placebo-Controlled Study (IRON CLAD)

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

A 19-Year Retrospective Analysis of Venous Thromboembolism Trends in Chemotherapy-Induced Anemia: Red Blood Cell Transfusion Versus Erythrocyte Stimulating Agent Administration

Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)

Ovarian Vein Thrombus: Is Treatment Necessary?

A Longitudinal Definition of the Value of Cancer Drugs

AMC-053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas

AMC-085: A Pilot Trial of AVD and Brentuximab Vedotin in the Upfront Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma. A Trial of the AIDS Malignancy Consortium

Readmission Rates Due To Venous Thromboembolism In Cancer Patients After Abdominopelvic Surgery

Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

A Retrospective Study On the Efficacy of Relative Dose Intensities of Non-Hodgkin's Lymphoma Treatments: Response to Chemotherapy and Overall Survival.

Pre- and Post-National Coverage Determination (NCD) Hematologic Outcomes and Blood Utilization in Cancer Patients with Chemotherapy-Induced Anemia (CIA): Results From a Multicenter Chart Review.

Venous Thromboembolism (VTE) and Survival in a Cancer Chemotherapy Outpatient Clinic: A Retrospective Chart Review Validation of a VTE Predictive Model.

Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim in Two Phase 3 Placebo-Controlled Clinical Trials.

Manageable Side Effects of Intravenous Iron in a Community Practice

Assessment of the Anemia Work up Prior to the Use of Erythropoiesis Stimulating Agents (ESA) in Cancer Patients Undergoing Chemotherapy in a Community Oncology Practice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only